Induction TPF versus adjuvant PF after CCRT in locally advanced nasopharyngeal carcinoma: A multicenter, randomized controlled phase III clinical trial.
Radiother OncolAug 16, 2026 (epub)
Clinical ResearchOncology (Medical)
Qianyong He, Yuanyuan Li, Jinhua Long et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, randomized controlled phase III trial evaluated the efficacy and safety of TPF induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) versus CCRT followed by PF adjuvant chemotherapy in 266 patients with locally advanced nasopharyngeal carcinoma. The 3-year progression-free survival was similar between groups, with 79% for the TPF group and 74.5% for the PF group (P = 0.454).
Key findings
- 3-year progression-free survival was 79% for the TPF group and 74.5% for the PF group (P = 0.454).
- The IC group had fewer grade toxic effects during CCRT, including nausea/vomiting and dry mouth.
- However, the IC group experienced increased rates of grade 3-4 leukopenia and neutrophilia.
Why it matters
Understanding the comparative efficacy and safety of different chemotherapy regimens in locally advanced nasopharyngeal carcinoma is crucial for optimizing treatment strategies and managing patient outcomes effectively.